Latest News On Prescription Drugs

Latest KFF Health News Stories

Estados desafían a Biden a que baje precios de medicamentos permitiendo importaciones desde Canadá

KFF Health News Original

En Estados Unidos se pagan unos de los precios más altos del mundo por los productos farmacéuticos de marca. Los medicamentos son generalmente menos caros en el vecino Canadá, donde el gobierno controla los precios.

States Challenge Biden to Lower Drug Prices by Allowing Imports From Canada

KFF Health News Original

Colorado has joined Florida, New Hampshire, and New Mexico in seeking federal permission to import prescription drugs from Canada. President Joe Biden endorsed the approach in his 2020 campaign but has yet to approve any state plan.

KHN’s ‘What the Health?’: Congress Races the Clock

KFF Health News Original

Sen. Raphael Warnock’s re-election in Georgia will give Democrats a clear-cut Senate majority for the first time in nearly a decade. Meanwhile, the current Congress has only days left to tackle major unfinished business on the health agenda, including fending off scheduled pay cuts for doctors and other health providers in the Medicare program. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Anna Edney of Bloomberg News, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

Empresas de capital riesgo invierten en el negocio de los ensayos clínicos de medicamentos. ¿Cuál es el riesgo para los pacientes?

KFF Health News Original

Para lanzar un nuevo fármaco al mercado, la Administración de Alimentos y Medicamentos (FDA) exige a las farmacéuticas estudios exhaustivos para demostrar su seguridad y eficacia. Conseguir que un medicamento salga al mercado unos meses antes, y con menos gastos de lo habitual, puede traducirse en beneficios millonarios para el fabricante.

Defense Department Health Plan Cuts Its Pharmacy Network by Nearly 15,000 Outlets

KFF Health News Original

Many of the pharmacies were small, independent operations that had decided not to participate next year because of the lowered reimbursement being offered. But they were surprised by an early dismissal, and some patients with specialized drug needs could face difficulties in the transition.

KHN’s ‘What the Health?’: Biden Hits the Road to Sell Democrats’ Record

KFF Health News Original

With the midterm elections rapidly approaching, President Joe Biden has taken to the road to convince voters that he and congressional Democrats have delivered for them during two years in power. Among the health issues highlighted by the administration this week are pandemic preparedness and the availability of over-the-counter hearing aids. The president also promised to sign a bill codifying the abortion protections of Roe v. Wade if Democrats maintain control of the House and Senate — even though it’s a long shot that there will be enough votes for that. Sarah Karlin-Smith of the Pink Sheet, Sandhya Raman of CQ Roll Call, and Mary Agnes Carey of KHN join KHN’s Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

Médicos se apresuran a usar fallo de la Corte Suprema para liberarse de cargos por opioides

KFF Health News Original

En una decisión de junio, el tribunal dijo que los fiscales no solo deben probar que una receta no estaba médicamente justificada sino también que el que la escribió sabía del riesgo de recetar opioides.

KHN’s ‘What the Health?’: Wrapping Up Summer’s Health News

KFF Health News Original

President Joe Biden has signed the Inflation Reduction Act and Congress is gone until after Labor Day. But the administration and lawmakers left lots of health policy achievements behind, including new rules to facilitate the sale of over-the-counter hearing aids and a potential reorganization of the Centers for Disease Control and Prevention. Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s Julie Rovner to discuss these issues and more. Also, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.

Para las familias médicamente vulnerables, la presión de la inflación es inevitable

KFF Health News Original

Para millones de familias que viven con enfermedades crónicas, trastornos cardíacos, diabetes y cáncer, u otras condiciones debilitantes, la inflación está demostrando ser un doloroso flagelo que podría perjudicar su salud.

For Medically Vulnerable Families, Inflation’s Squeeze Is Inescapable

KFF Health News Original

Inflation hasn’t hit Americans like this in decades. And families living with chronic diseases have little choice but to pay more for the medicine, supplies, and food they need to stay healthy.

Watch: Explaining the Nitty-Gritty of Medicare Drug Price Negotiations — And Patients’ Potential Savings

KFF Health News Original

KHN chief Washington correspondent Julie Rovner discusses the Senate Democrats’ plans to let Medicare negotiate some drug prices, cap out-of-pocket drug costs for seniors, and fund enhanced subsides for ACA marketplace health plans.

Lo que debes saber sobre Paxlovid para tratar covid, en especial, ¿debes tomarlo?

KFF Health News Original

Desde que Paxlovid comenzó a estar disponible hace siete meses, ha eclipsado otras terapias disponibles para prevenir los síntomas graves de covid en pacientes de alto riesgo. Algunos médicos se apresuran a recetarlo, pero como ocurre con tanto sobre la pandemia de covid, hay controversia.

Everything You Need to Know About Paxlovid — Especially, Should You Take It?

KFF Health News Original

Paxlovid has eclipsed other available therapies for preventing life-threatening covid symptoms in high-risk patients. But even as doctors praise its effectiveness, many say they have unanswered questions about prescribing the drug and want more and better data about it.